Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOCOGAMI: Empagliflozin in newly detected glucose abnormalities after myocardial infarction
2015-004571-73Phase 4Completed
- Sponsor
- Karolinska Institutet
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of empagliflozin in myocardial infarction (MI), unstable angina, prediabetes and 1 more, sponsored by Karolinska Institutet. Primary endpoint: Changes in cardiovascular magnetic resonance (CMR) measures. Started Jan 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)unstable anginaprediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-004571-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004571-73.